GBP121.66
0.18% today
London, Sep 05, 11:15 am CET
ISIN
GB0009895292
Symbol
AZN

AstraZeneca Stock price

GBP121.88
+11.29 10.21% 1M
+2.08 1.73% 6M
+19.42 18.95% YTD
-5.82 4.55% 1Y
+21.98 22.01% 3Y
+50.81 71.49% 5Y
+91.16 296.77% 10Y
+109.93 919.76% 20Y
London, Closing price Thu, Sep 04 2025
-0.22 0.18%
ISIN
GB0009895292
Symbol
AZN
Industry

Key metrics

Basic
Market capitalization
GBP189.3b
Enterprise Value
GBP208.4b
Net debt
GBP19.2b
Cash
GBP5.3b
Shares outstanding
1.6b
Valuation (TTM | estimate)
P/E
30.9 | 17.5
P/S
4.5 | 4.3
EV/Sales
5.0 | 4.7
EV/FCF
34.2
P/B
5.7
Dividends
DPS
GBP2.46
Yield 1Y | 5Y
2.0% | 2.5%
Growth 1Y | 5Y
7.8% | 2.4%
Payout 1Y | 3Y
73.3% | 91.8%
Increased
1 Year
Financials (TTM | estimate)
Revenue
GBP42.1b | GBP44.5b
EBITDA
GBP13.2b | GBP16.0b
EBIT
GBP10.3b | GBP14.1b
Net Income
GBP6.2b | GBP10.8b
Free Cash Flow
GBP6.1b
Growth (TTM | estimate)
Revenue
15.0% | 10.6%
EBITDA
27.4% | 30.2%
EBIT
37.0% | 48.9%
Net Income
28.8% | 105.7%
Free Cash Flow
17.5%
Margin (TTM | estimate)
Gross
82.1%
EBITDA
31.3% | 36.0%
EBIT
24.4%
Net
14.7% | 24.2%
Free Cash Flow
14.5%
Financial Health
Equity Ratio
39.2%
Return on Equity
17.3%
ROCE
17.5%
ROIC
14.5%
Debt/Equity
0.7
More
EPS
GBP4.0
FCF per Share
GBP3.9
Short interest
-
Employees
94k
Rev per Employee
GBP430.0k
Show more

Create a Free Account to create an AstraZeneca alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

AstraZeneca Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

29x Buy
85%
5x Hold
15%

Analyst Opinions

34 Analysts have issued a AstraZeneca forecast:

Buy
85%
Hold
15%

Financial data from AstraZeneca

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
42,061 42,061
15% 15%
100%
- Direct Costs 7,540 7,540
16% 16%
18%
34,521 34,521
15% 15%
82%
- Selling and Administrative Expenses 11,626 11,626
2% 2%
28%
- Research and Development Expense 9,815 9,815
20% 20%
23%
13,182 13,182
27% 27%
31%
- Depreciation and Amortization 2,922 2,922
2% 2%
7%
EBIT (Operating Income) EBIT 10,260 10,260
37% 37%
24%
Net Profit 6,175 6,175
29% 29%
15%

In millions GBP.

Don't miss a Thing! We will send you all news about AstraZeneca directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AstraZeneca Stock News

Negative
Reuters
one day ago
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Positive
Seeking Alpha
3 days ago
Since last month, AstraZeneca's shares have trounced the S&P 500 index. The drugmaker has an impressive drug portfolio and a deep pipeline, which should continue to drive core EPS growth for the foreseeable future. AstraZeneca's net debt to EBITDA ratio has modestly improved so far in 2025, making an already vigorous balance sheet even stronger.
Positive
Proactive Investors
4 days ago
Among the noise of tariffs, drug pricing reforms, and shifting investor sentiment, AstraZeneca PLC (LSE:AZN) has quietly delivered a clear result: its experimental blood pressure treatment, baxdrostat, works
More AstraZeneca News

Company Profile

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Pascal Soriot
Employees 94,300
Founded 1992
Website www.astrazeneca.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today